Junshi Biosciences (688180.SH): JS001sc Meets Primary Endpoint in Phase III Trial for First-Line Treatment of Non-Squamous NSCLC

Stock News11-24

Junshi Biosciences (688180.SH) announced that its product, toripalimab injection (subcutaneous) (code: JS001sc), has met the primary endpoint in a multicenter, open-label, randomized controlled Phase III clinical study (JS001sc-002-III-NSCLC, NCT06505837). The trial compared JS001sc with toripalimab injection (brand name: Tuoyi®, code: JS001) combined with chemotherapy as a first-line treatment for recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC). The company plans to submit a marketing authorization application for JS001sc to regulatory authorities soon.

JS001sc is a subcutaneous formulation developed based on the marketed toripalimab injection. It is the first domestically developed anti-PD-1 monoclonal antibody subcutaneous preparation to enter Phase III clinical trials, potentially offering greater convenience for patients. As of the announcement date, the Phase III study evaluating JS001sc versus toripalimab injection plus chemotherapy for first-line treatment of recurrent or metastatic non-squamous NSCLC has successfully achieved its primary endpoint.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment